2015 American Transplant Congress
Immunoglobulin G Donor-Specific Anti-HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Experimental and clinical data suggest that antibodies have different pathogenicities according to their IgG subclasses. We investigated the association between IgG subclasses of circulating anti-HLA…2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…2015 American Transplant Congress
Does Ureteric Stent Avoid Urological Complications After Renal Transplantation? A Retrospective Study of 10 Years Experience
Divison of Urology, Renal Transplantation Unit, University of São Paulo, São Paulo, SP, Brazil.
PURPOSE: Urinary leakage and ureteral stenosis are the most common surgical complications after kidney transplantation and are associated with significant morbidity, mortality and prolonged hospital…2015 American Transplant Congress
Risk Stratification in Tailoring Induction Therapy in Kidney Transplant Recipients(KTR): Is It Cost-Effective?
Transplant, Univ. of Utah, Salt Lake City, UT.
Intro: Selecting induction therapy based on immunologic risk in KTR has gained popularity but there has yet to be a study evaluating the cost beyond…2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
1Emory University, Atlanta; 2Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…2015 American Transplant Congress
Pre-Transplant Donor Specific Antibody With Negative Flow-Crossmatch Was Related to Higher Acute Rejection But Not to Poor Graft Survival
Background: DSA have been associated to lower graft survival and a higher humoral rejection rate, but there is a concern about the clinical impact of…2015 American Transplant Congress
Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients
1Transplant, Mayo Clinic, Jacksonville, FL; 2Pharmacy, Mayo Clinic, Jacksonville, FL.
Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients…2015 American Transplant Congress
Associations of Pre-Transplant Prescription Narcotic Use With Clinical Complications After Kidney Transplantation
Background: Associations of narcotic use before kidney transplantation with post-transplant clinical outcomes are not well described.Methods: We performed a retrospective analysis of linked national registry…2015 American Transplant Congress
Hypothermic Machine Perfusion Improves Kidney Viability through Amelioration of Vasospasm and Edema of Podocytes and Renal Tubular Epithelial Cells
Hypothermic machine perfusion (MP) may improve outcome after transplantation from donors after cardiac death (DCD) kidneys, but protective mechanisms of MP remain largely unknown. To…2015 American Transplant Congress
Treatment of Hepatitis C Virus in Kidney Transplant Recipients With Direct Acting Anti-Viral Agents: Early Results in 12 Cases
Background: Recently approved direct acting antiviral agents (DAA) for treatment of HCV are interferon sparing allowing an attractive treatment option for kidney transplant recipient with…
- « Previous Page
- 1
- …
- 487
- 488
- 489
- 490
- 491
- …
- 531
- Next Page »